Who Paid My Doc
Fibryga
Biological Intensive Careemergency
NDC 68982-347-01
General payments
$219,172
Research payments
$144,213
Through program year 2025, $219,172 in general payments and $144,213 in research payments were reported against Fibryga (Intensive Careemergency).
No combined total These are different kinds of money, reported under different rules. A meal and a clinical trial grant do not add up to anything meaningful, so this site does not add them.
By program year
9 rows| Year | Kind | Amount | Payments |
|---|---|---|---|
| 2025 | General | $70,725 | 2,667 |
| 2024 | General | $2,456 | 92 |
| 2023 | General | $38,812 | 77 |
| 2023 | Research | $65,774 | 7 |
| 2022 | General | $30,657 | 52 |
| 2021 | General | $18,720 | 36 |
| 2021 | Research | $78,439 | 3 |
| 2020 | General | $49,219 | 98 |
| 2019 | General | $8,582 | 92 |
Breakdown
The top 5 of the 100 largest recipients; each share is of general payments naming this product in 2025.
The top 5 of 76 specialties; each share is of general payments naming this product to practitioners with a specialty in 2025. Each practitioner is counted under their primary specialty.
The top 5 of 48 states; each share is of general payments naming this product in 2025 where a state was reported.
Records
3,114 general · 10 researchEvery payment, record by record
Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.
What you are looking at
Manufacturers name the drug, biological or device a payment relates to. CMS does not give products their own identifiers, so a product here is assembled from how it was reported — a brand may appear under more than one spelling, and this page covers one of them rather than the brand as a whole.